Article | Open

Transient auditory nerve demyelination as a new mechanism for hidden hearing loss

  • Nature Communications 8, Article number: 14487 (2017)
  • doi:10.1038/ncomms14487
  • Download Citation
Published online:


Hidden hearing loss (HHL) is a recently described auditory neuropathy believed to contribute to speech discrimination and intelligibility deficits in people with normal audiological tests. Animals and humans with HHL have normal auditory thresholds but defective cochlear neurotransmission, that is, reduced suprathreshold amplitude of the sound-evoked auditory nerve compound action potential. Currently, the only cellular mechanism known for HHL is loss of inner hair cell synapses (synaptopathy). Here we report that transient loss of cochlear Schwann cells results in permanent auditory deficits characteristic of HHL. This auditory neuropathy is not associated with synaptic loss, but rather with disruption of the first heminodes at the auditory nerve peripheral terminal. Thus, this study identifies a new mechanism for HHL, highlights the long-term consequences of transient Schwann cell loss on hearing and might provide insights into the causes of the auditory deficits reported in patients that recover from acute demyelinating diseases such as Guillain–Barré syndrome.


In the mammalian cochlea, acoustic stimuli are detected by inner hair cells (IHCs), which transduce and transform them into synaptic signals to the primary auditory sensory neurons, the spiral ganglion neurons (SGNs). These neurons then relay the acoustic information to the central auditory circuits. Thus, proper function of both sensory cells and neurons is essential for normal hearing and auditory communication, and degeneration of either component causes sensorineural hearing loss. This type of hearing loss, which affects 320 million people worldwide1, is characterized by permanent elevation of auditory thresholds, that is, the minimal sound pressure levels (SPLs) that evoke an auditory or neural response at specific sound frequencies. Until recently, it was believed that auditory processing is normal in subjects with normal thresholds, even after recovery from a temporary threshold shift (TTS) due to noise exposure, and that hearing deficits in those cases were due to central problems2. However, recent animal and human studies indicate that moderate noise exposures or ageing can result in a new form of peripheral hearing loss called ‘hidden hearing loss (HHL)’3,4,5,6. HHL can be detected physiologically and is characterized by normal auditory thresholds but reduced suprathreshold amplitude of the sound-evoked SGN compound action potential (AP) (the first peak of the auditory brainstem response (ABR) waveform)3,5,6,7,8, and by the alteration in the ratio between the peak of the ABR waveform generated by hair cells (summating potential (SP)) and the peak I of the ABR waveform (AP)9. The reduced neuronal activation seen in HHL has been proposed to result in degradation of the temporal coding of suprathreshold sounds and deficits in speech discrimination and intelligibility, particularly in a noisy environment10,11; however, the latter are not diagnostic of HHL, as they could be also caused by central processing deficits. HHL has been proposed to lead to hyperactivation of central auditory synapses, thus possibly contributing to tinnitus3,12. Until now, loss or dysfunction of IHC synapses has been the only proposed mechanism of HHL13. Here we report an additional cellular mechanism for HHL.

In the cochlea, sensory hair cells and neurons are in close association with several types of glial and glia-like cells14. Hair cells are surrounded by supporting cells, SGN axons are myelinated by Schwann cells and spiral ganglion cell bodies are wrapped by satellite cells (Fig. 1a). In prior studies we explored the roles of supporting cells in IHC synapse formation and regeneration15 and in the preservation of hair cells16. As part of our ongoing efforts to define the roles the different populations of cochlear glia play in hearing and deafness15,16,17, we investigated the consequences of Schwann cell ablation in the mature cochlea. We found that acute Schwann cell loss causes rapid auditory nerve demyelination, which is followed by robust Schwann cell regeneration and axonal remyelination. Surprisingly, this transient Schwann cell loss results in a permanent auditory impairment characteristic of HHL. However, this HHL differs from that seen after noise exposure or ageing in that it occurs without alterations in synaptic density but rather correlates with a specific and permanent disruptions of the first heminodes at the auditory nerve axon close to the IHCs. Furthermore, the two types of HHL occur independently (noise exposures that cause HHL do not disrupt heminodes) and they are additive. Together, these results uncover a new mechanism for the pathogenesis of HHL and a new consequence of myelin defects on the normal function of the nervous system.

Figure 1: Plp1 is expressed only by Schwann and satellite cells in the mature cochlea.
Figure 1

(a) Schematic illustration of the IHC, SGNs and their associated glial/glial-like cells. (be) Images of the organ of Corti of Plp1/eGFP mice at different postnatal ages (P3–P35) show that the Plp1 promoter is active in supporting cells associated with IHCs until P15, but by P21 is silent. Three rows of outer hair cells (OHCs) and one row of IHCs were labelled by Myo7a. (fi) Images of cochlear whole mounts of Plp1/eGFP mice show that the Plp1 promoter is active in auditory nerve Schwann cells in the OSL at all ages examined. (jm) Images of sections through the spiral ganglion of Plp1/eGFP mice show that the Plp1 promoter is active in satellite cells surrounding SGNs at all ages examined. Sections were co-labelled with a marker for glial cells (Sox2) and nuclei (4,6-diamidino-2-phenylindole, DAPI). Asterisks and arrow heads indicate SGN cell bodies and associated satellite cells, respectively.


Ablation and regeneration of Schwann cells in mature cochlea

To test the consequence of Schwann and satellite cell ablation on the cochlea, we used conditional expression of diphtheria toxin fragment A (DTA) in proteolipid protein 1 (Plp1)-expressing cells at P21. This strategy was based on the pattern of Plp1 promoter activity in the postnatal cochlea. As shown in Fig. 1, in the neonatal mouse cochlea (P1–P15) Plp1 is expressed by Schwann cells, satellite cells, as well as inner phalangeal and inner border cells (IPhC/IBCs), the supporting cells surrounding IHCs18. However, by P21 Plp1 promoter activity in IPhC/IBCs is undetectable (Fig. 1a–e), while is maintained in Schwann cells along the auditory nerve fibres (ANFs) located at the osseous spiral lamina (OSL) (Fig. 1a,f–i) and satellite cells surrounding the cell bodies of SGNs in Rosenthal’s canal (Fig. 1a,j–m).

As anticipated from prior studies of mice with DTA-induced ablation of Plp1-expressing cells19, tamoxifen intraperitoneal (i.p.) injection to mice carrying Plp1/CreERT transgene and Rosa26DTA alleles [DTA(+/−):Plp1/Cre(+/−)] from P21 to 23 resulted in uncoordinated gait and hind-limb paralysis between 1 and 2 weeks post DTA expression followed by complete recovery of normal gait by 3–4 weeks post DTA expression. This is consistent with the robust regenerative capacity of Plp1-expressing glia cells19. Interestingly, although DTA induction at P35 results in significant mortality 3 weeks later (ref. 19 and our unpublished data), we found that ablation of Plp1-expressing cells at P21 does not result in lethality. These observations suggest that the health effects of loss of Plp1+ cells increase with age.

Based on the findings described in Fig. 1, we anticipated that tamoxifen treatment of DTA(+/−)/PlpCre1(+/−) mice from P21 to P23 would ablate Schwann and satellite cells without affecting the supporting cells in the organ of Corti. Indeed, immunostaining of cochlear whole mounts with the Schwann cell marker Sox10 or myelin basic protein (MBP) showed that DTA transgene activation at P21 results in robust ablation of Schwann cells along the ANFs within 1 week after tamoxifen injection (Supplementary Fig. 1a–d). In contrast, IPhC/IBCs, which are labelled by Sox2 or GLAST, are spared from DTA-mediated ablation at this age (Supplementary Fig. 1e,f). With this model in hand, we analysed the effects of the Schwann cell loss on cochlear structure and function at different intervals, from 1 week to 1 year after induction of Schwann cell ablation.

Studies of other peripheral nerves have demonstrated that demyelination and Schwann cell loss is usually followed by extensive proliferation of undifferentiated Schwann cells, which repopulate and remyelinate the nerves20,21. Accordingly, analysis of 5-ethynyl-2′-deoxyuridine (EdU) incorporation showed that 1 week after DTA transgene activation, the auditory nerves of mice with Schwann cell ablation display a dramatic increase in the number of EdU+ cells (Fig. 2c,d) compared with controls (Fig. 2a,b). Furthermore, lineage tracing with an inducible tdTomato reporter in DTA(+/−):tdTomato(+/−):Plp1/Cre(+/−) mice revealed that these EdU-positive cells are generated by Plp1-expressing cells that most probably escaped DTA-mediated ablation (Fig. 2e–h), that is, Schwann cells in which recombination occurred in the Rosa26tdTomato allele but not in the Rosa26DTA allele. Further analysis showed that the surviving tdTomato+ cells 1 week post induction (Fig. 2i,j) repopulate the OSL to levels similar to that of controls by 1 month post induction (Fig. 2k,l).

Figure 2: Schwann cells in the auditory nerve regenerate within weeks after DTA induction in Plp1-expressing cells.
Figure 2

(ad) Tamoxifen induction of DTA expression at P21 promotes EdU incorporation in DTA(+/−):Plp1/Cre(+/−) cochlea (c,d), but not the control cochlea (a,b). Mice were injected with tamoxifen at P21–23, with EdU at P29 and tissues harvested at P30. (b,d) High-magnification views of the dashed boxes in a and c, respectively. HP, habenula perforata; oC, organ of Corti; OSL, osseous spiral lamina. (eh) Lineage tracing of EdU+ cells shows that they are Schwann cells that escaped DTA-mediated death. (h) Merged image of EdU labelling (e, green), Plp1-driven tdTomato (f, red) and nuclei (g, blue). Arrow heads in h indicate surviving Plp1-expressing cells incorporated EdU. (il) tdTomato-positive cells repopulate in 4 weeks after tamoxifen induction. Control (i,k) and DTA(+/−):tdTomato(+/−):Plp1/Cre(+/−) mice (j,l) were injected with tamoxifen from P21 to 23 and cochlear tissues analysed either 1 week (i,j, Tmx+1 week) or 4 weeks (k,l, Tmx+4 weeks) later.

Similar robust regeneration was observed for satellite cells (Supplementary Fig. 2). Although satellite cells are clearly lost 1 week post induction (Supplementary Fig. 2a,b), they repopulate within 2 weeks post induction in DTA(+/−):Plp1/eGFP(+/−):Plp1/Cre(+/−) cochlea (Supplementary Fig. 2c,d). Plastic sections of Rosenthal’s canal 16 weeks post induction show that both the SGN cell body density (Supplementary Fig. 2e–g) and the percentage of SGN cell bodies wrapped by satellite cells (Supplementary Fig. 2e,f,h) are similar in DTA(+/−):Plp1/Cre(+/−) and control cochlea. Together, these results indicate that cochlear Schwann and satellite cells spontaneously and robustly repopulate after DTA-mediated ablation in the mature cochlea, and that Schwann cell regeneration is at least partly mediated by proliferation of the surviving Schwann cells.

Schwann cell regeneration and remyelination of SGN axons

In models of axon injury or demyelinating neuropathy, damaged Schwann cells regenerate and re-myelinate axons20,22,23. We therefore examined the consequence of DTA-induced Schwann cell ablation on ANF myelin. DTA expression resulted in acute demyelination of the ANFs within 1 week post induction (Fig. 3a,b), consistent with loss of Schwann cell markers at this time point (Supplementary Fig. 1). At 4 weeks post induction, when Schwann cells have repopulated (Fig. 2i,j), we observed significant yet incomplete remyelination (Fig. 3a,b). By 16 weeks post induction, myelinated axon density completely recovered in DTA(+/−):Plp1/Cre(+/−) cochleas (Fig. 3a,b). Moreover, at 16 weeks post induction, axons from DTA(+/−):Plp1/Cre(+/−) cochleas had normal axon diameters (Fig. 3c,e,g) and myelin thickness (Fig. 3d,f,g). These results indicate that acute Schwann cell ablation results in rapid cell regeneration followed by remarkable remyelination, leading to fibres with normal axon caliber and myelin thickness.

Figure 3: Transient Schwann cell ablation causes acute demyelination followed by remyelination of the ANFs.
Figure 3

(a,b) Representative electron micrographs of sections through the OSL show ANF in DTA(+/−):Plp1/Cre(+/−) cochlea are demyelinated at 1 week after tamoxifen injection, followed by partial remyelination 4 weeks later and complete remyelination at 16 weeks. Arrowheads show pathological myelin sheaths and asterisks show partially re-myelinated axons. (b) Quantitative analysis of myelinated axon density in the OSL at different times after tamoxifen treatment; n=10–16 from 3 individual animals in each group. *P<0.05 and ***P<0.001 by two-way analysis of variance (ANOVA) followed by Bonferroni’s post-test. (cg) ANFs of DTA(+/−):Plp1/Cre(+/−) cochlea have normal axon caliber and myelin thickness 16 weeks after tamoxifen induction. Axonal diameter (c,e) and g-ratio (d,f,g) are normal in DTA(+/−):Plp1/Cre(+/−) cochleae 16 weeks after tamoxifen treatment. g-ratio was calculated as axon diameter / (axon+myelin sheath diameter). For eg, n=3 animals of each group with>300 axons per group. Data are expressed as mean±s.d.

Transient Schwann cell ablation causes permanent HHL

Conduction block is the fundamental finding in clinically important acquired demyelinating neuropathies such as acute inflammatory demyelinating polyneuropathy and chronic inflammatory demyelinating polyneuropathy24. Therefore, given the dramatic demyelination we observed in ANFs on activation of the DTA transgene, we anticipated that mice would display significant hearing abnormalities soon after induction, and that these defects would resolve within 4 months as the nerve remyelinated. However, thresholds for the ABR and distortion product otoacoustic emission (DPOAE), which reflect the function of IHCs and outer hair cells, respectively, were not affected by the lack of myelin in ANFs (Supplementary Fig. 3a,b), indicating that these mice were ‘audiologically normal.’ In contrast, the suprathreshold amplitudes of the ABR peak 1 (P1 amplitudes), which represent the summed activity of the SGNs, were significantly reduced (Fig. 4a and Supplementary Fig. 4). Furthermore, the suprathreshold latencies and widths of the ABR peak 1, which reflect in part the conduction velocity of the auditory nerve, were both severely affected (Fig. 4b,c and Supplementary Fig. 5). Specifically, mice with DTA-induced Schwann cell ablation have increased P1 latencies (Fig. 4b and Supplementary Fig. 5) and P1 widths (Fig. 4c) at all cochlear frequencies examined (5.6–32 kHz). Surprisingly, the effects of Schwann cell ablation on P1 amplitudes, latencies and widths do not reverse even 16 weeks post induction, when Schwann cells and myelin have regenerated (Figs 2 and 3 and Supplementary Fig. 2). Further support to the conclusion that the transient demyelination results in HHL was provided by analysis of the SP/AP ratios (amplitudes of SP/amplitudes of AP) (Fig. 5a), which can be used as a differential diagnosis for HHL in both mice and humans5,9. Transient Schwann cell ablation did not affect SP at all time points (Fig. 5b), further demonstrating that Schwann cell loss did not alter hair cell function (Supplementary Figs 1 and 3). In contrast, peak 1 AP amplitudes in DTA(+/−):Plp1/Cre(+/−) mice were reduced at all time points (Fig. 5c), suggestive of cochlear neural dysfunction. Furthermore, SP/AP ratios were significantly reduced 4–16 weeks after Schwann cell ablation (Fig. 5d). These findings indicate that transient Schwann cell ablation results in prolonged auditory neuropathy and HHL.

Figure 4: Transient Schwann cell ablation results in persistent impairment of auditory physiology.
Figure 4

Mice were injected with tamoxifen from P21 to 23 and ABR tests were performed 1, 4, 8 and 16 weeks later. At all time points examined, ABR P1 supra-threshold amplitudes (a) are reduced, ABR P1 latencies (b) are increased and ABR P1 widths (c) are increased in DTA(+/−):Plp1/Cre(+/−) mice. ABR P1 amplitudes, latencies and widths were analysed at 70 dB SPL. Tmx+1 week, n=17–21; Tmx+4 weeks, n=16–20; Tmx+8 weeks, n=10–14; Tmx+16 weeks, n=7–8 of each animal group. ***P<0.001 by two-way ANOVA. Data are expressed as mean±s.e.m.

Figure 5: Auditory APs and SPs are differentially affected by transient Schwann cell ablation.
Figure 5

Mice were injected with tamoxifen from P21 to 23 and ABR tests were performed 1, 4, 8 and 16 weeks later. (a) Averaged ABR traces of control and DTA(+/−):Plp1/Cre(+/−) mice at 11.3 kHz, 70 dB SPL. Five ABR peaks are labelled with I-V. Arrows indicate SP and ABR P1 AP. (b) The SP of DTA(+/−):Plp1/Cre(+/−) mice are not affected at all time points examined. (c) ABR P1 AP were reduced in DTA(+/−):Plp1/Cre(+/−) mice at all time points examined. (d) Ratios of SP/AP are increased in DTA(+/−):Plp1/Cre(+/−) mice 4, 8 and 16 weeks after tamoxifen induction. Tmx+1 week, n=17–21; Tmx+4 weeks, n=16–20; Tmx+8 weeks, n=10–14; Tmx+16 weeks, n=7–8 of each animal group. *P<0.05, **P<0.01 and ***P<0.001 by two-way ANOVA. Data are expressed as mean± s.e.m.

Demyelination-induced HHL is not caused by synapse loss

Loss of synapses between IHCs and SGNs is currently the only known histological correlate of HHL10,11 and synapse loss has been reported to occur in some demyelinating disorders, for example, in Charcot–Marie–Tooth (CMT) disease25 and multiple sclerosis26. Therefore, we analysed the density of IHC ribbon synapses in control and demyelinated mice by immunostaining for the presynaptic ribbon and postsynaptic receptor patches using antibodies against CtBP2 and GluA2 (ref. 15). At 4 weeks post induction, when remyelination was complete but HHL was robust, IHC synapse density was the same in DTA(+/−):Plp1/Cre(+/−) and control cochleas at all regions examined (Fig. 6). This data indicates that transient loss of glial cells results in prolonged auditory deficits and HHL by a mechanism that is distinct from cochlear synaptopathy.

Figure 6: Transient cochlear Schwann cell ablation does not affect ribbon synapse density.
Figure 6

(a,b) Representative images of ribbon synapses immunostained with GluA2 (green) and Ctbp2 (red) from control (a) and DTA(+/−):Plp1/Cre(+/−) (b) mice 4 weeks after tamoxifen induction. (c) Quantitative analyses of ribbon synapse counts per IHC at 8, 16 and 32 kHz cochlear regions. n=4 of each animal group. Data are expressed as mean±s.d.

HHL is associated with permanent heminodal disruption

The observation that ABR P1 latency is longer after transient demyelination suggested that other aspects of myelin–axon interactions could be disrupted. Therefore, we examined whether the transient demyelination alters node of Ranvier density in auditory axons. Immunostaining for the paranodal protein Caspr27 in combination with the myelin protein Plp1 showed that in the control P30 cochlea, nodes of Ranvier can be clearly observed along the ANFs in OSL (Fig. 7a), whereas heminodes formed by the first Schwann cells close to the IHCs can be seen at the habenula perforata (HP), the perforations in the OSL through which auditory fibres pass on their way to and from the organ of Corti (Fig. 7a, see also Fig. 1a). Interestingly, the first 50 μm of the auditory nerve after the heminodes has a low density of nodes of Ranvier, indicating that consistent with previous reports28,29, the myelin segments generated by the Schwann cells closest to the IHC are about that length. As expected for a severely demyelinated nerve, the appearance of nodes and heminodes was disrupted in DTA(+/−):Plp1/Cre(+/−) cochlea 1 week after DTA induction (Fig. 7b). Quantification of nodal density using co-immunostaining for Caspr and the nodal protein gliomedin30 showed that 1 week after Schwann cell ablation, many nodes of Ranvier are lost in the OSL and the remaining ones have irregular appearance (Fig. 7c,d,i). Yet, consistent with the extensive remyelination, node of Ranvier density in the OSL completely regenerated by 4 weeks post induction, their appearance being indistinguishable from the controls (Fig. 7c–i).

Figure 7: Transient Schwann cell ablation causes acute disruption of nodal structures followed by complete recovery of node of Ranvier density in ANFs in the OSL.
Figure 7

(a,b) Both cochlear heminodes and nodes of Ranvier are disrupted in DTA(+/−):Plp1/Cre(+/−) mice at 1 week after tamoxifen induction. Tissues are immunostained for Plp1 (red) and Caspr (green). (ch) Representative images showing that nodes of Ranvier at OSL are disrupted in DTA(+/−):Plp1/Cre(+/−) cochlea at different times after tamoxifen treatment (d,f,h) compared with their corresponding controls (c,e,g). Nodes of Ranvier are lost in DTA(+/−) mice 1 week after tamoxifen induction (d) but recover 4 weeks (f) and 16 weeks (h). (i) Node of Ranvier density quantification in DTA(+/−):Plp1/Cre(+/−) and control mice at different times after tamoxifen treatment; n=6–8 of each animal group. ***P<0.001 by two-way ANOVA followed by Bonferroni’s post test. Data are expressed as mean±s.d.

In contrast, at the heminode zone and the area occupied by the first Schwann cells, Caspr and gliomedin localization did not recover normally. As shown in Fig. 7a,b, heminodes are dramatically disrupted 1 week after Schwann cell ablation compared with the control (Fig. 8a,b). In the control normal cochlea (Fig. 8a,c,e), the heminodal immunostaining is tightly clustered within the last 20 μm segments of the myelinated axon terminals (herein defined as the heminode zone). Although there is significant recovery of Caspr and gliomedin localization at heminodes during the postinduction period, it does not return to control levels 4 months after the insult (Fig. 8b,d,f). Moreover, aberrant localization of nodal proteins is observed proximal to the heminode zone (Fig. 8d,f, below dashed lines and Fig. 8g), whereas virtually no nodal proteins are present in that area in controls. Immunostaining for other nodal markers (sodium channels (NaV), ankyrin G (AnkG) and β4-spectrin) also shows disruption of heminodal organization in DTA(+/−):Plp1/Cre(+/−) cochlea, further supporting the notion that Schwann cell–axon interactions in the area close to the HP are permanently affected by transient Schwann cell ablation (Supplementary Fig. 6). In contrast to the robust remyelination observed along the OSL, dysmyelinated fibres were observed at the axon segments closer to the HP. Immunostaining for neurofilament heavy chain (NFH), which labels unmyelinated axons31, labelled nerve fibres below the HP in the DTA(+/−):Plp1/Cre(+/−) cochlea but not in controls (Fig. 8h,i). Electron micrographs at the HP also illustrate the presence of unmyelinated fibres in DTA(+/−):Plp1/Cre(+/−) mice but not in controls (Fig. 8j,k).

Figure 8: Transient Schwann cell ablation causes permanent disruption of the heminodes and dysmyelination at the HP.
Figure 8

(af) Heminodes at the habenula perforata (HP) remain disorganized in DTA(+/−):Plp1/Cre(+/−) cochlea (b,d,f) compared control cochlea (a,c,e) at 1 week (a,c), 4 weeks (b,d) and 16 weeks (e,f) after tamoxifen induction. (g) Increased number of aberrant nodal staining (co-localized Caspr/Gliomedin) is observed in DTA(+/−):Plp1/Cre(+/−) cochlea outside the pre-defined 20 μm heminode zone as shown in af (below dashed lines, n=6–10 of each animal group). ***P<0.001 by two-way ANOVA followed by Bonferroni’s post test. Data are expressed as mean±s.d. (h,i) Immunostaining for NFH, which preferentially stains unmyelinated axons, indicates the presence of dysmyelinated ANFs as they reach the HP (i, arrow heads) 16 weeks after tamoxifen induction in DTA(+/−):Plp1/Cre(+/−) cochlea. This staining is absent in control mice (h). HP, habenula perforata; IHC, inner hair cells; OSL, osseous spiral lamina. IHCs are stained for Myo7a. (j,k) Representative electron micrographs show dysmyelinated nerve fibres beneath the HP in DTA(+/−):Plp1/Cre(+/−) cochlea (k) but not in control cochlea (j).

HHL persists 1 year after Schwann cell ablation

To determine whether the pathology observed 16 weeks after insult resolves with time, we studied a cohort of mice one year after DTA induction and found that the pathology remained unchanged. ABR thresholds remained normal in the DTA(+/−):Plp1/Cre(+/−) mice (Supplementary Fig. 7a), indicating that the transient Schwann cell degeneration did not jeopardize long-term cochlea health. However, similar to that in the earlier time points, ABR P1 amplitudes, latencies and widths remained abnormal and indicative of auditory neuropathy (Supplementary Fig. 7b–d). Furthermore, node of Ranvier markers remained disorganized in the HP region (Supplementary Fig. 7g,h) but not at the OSL (Supplementary Fig. 7e,f) in the DTA(+/−):Plp1/Cre(+/−) cochlea. In addition, unmyelinated axon segments at the HP region were also present (Supplementary Fig. 7i,j). These results demonstrate compromised Schwann cell–axon interactions in this specific domain within the auditory nerve even 1 year after transient Schwann cell loss.

Noise exposure causes HHL without affecting heminodes

Exposure of rodents to noise levels higher than those that induce TTSs and HHL (110 versus 98 dB SPL) results in permanent hearing loss (permanent threshold shifts) and central auditory demyelination32, raising the possibility that exposure to noise that induce TTS and HHL could also affect auditory nerve nodal structures. Therefore, we generated HHL in wild-type mice by exposing them to an octave-band noise (8–16 kHz, 98 dB SPL for 2 h)4,33. Two weeks after noise exposure, both ABR and DPOAE thresholds had recovered (Supplementary Fig. 8a,b), whereas the suprathreshold ABR P1 amplitudes were reduced at higher frequencies (Supplementary Fig. 8c). Consistent with previous reports15,34, ABR P1 latencies were not significantly affected by noise exposure (Supplementary Fig. 8d), whereas ribbon synapse loss was evident at 32 kHz but not 11.3 kHz, consistent with a high-frequency HHL due to synaptopathy (Supplementary Fig. 8e–i). In contrast, the heminodes at the HP appeared normal (Supplementary Fig. 8j–m), suggesting that exposure to synaptopathic noise does not alter nodal organization.

Noise- and demyelination-induced HHL are additive

The results described above indicate that two different types of HHL exist: one caused by noise and involving synaptopathy, and the other caused by transient Schwann cell loss and involving nodal disruption. To test whether these two forms of HHL interact, we subjected mice that had undergone demyelination (DTA(+/−):Plp1/Cre(+/−)) at 3 weeks of age and their control counterparts (DTA(+/−) mice) to noise exposure that causes synaptopathy at 8 weeks of age, and analysed their auditory function 2 weeks later (Fig. 9a). As shown above, 4 weeks after DTA-mediated Schwann cell ablation mice displayed HHL involving alterations in ABR Peak 1 amplitude and latency (Fig. 9b–d), which persisted even after noise exposure (Fig. 9e–g). Remarkably, noise exposure induced further decrease in ABR Peak 1 amplitudes beyond the one produced by demyelination (Fig. 9h–j) and the magnitudes of the shift in amplitudes were the same as in mice that had no demyelination (Fig. 9k–p). Furthermore, ABR P1 latencies remained unaffected after noise exposure in both demyelinated and control mice, indicating that the noise produced the same type of pathology independent of the prior demyelination (Fig. 9j,m,p). These findings indicate that exposure to synaptopathic noise causes additional degradation of neural output from the cochlea even when mice already suffer from HHL caused by transient Schwann cell loss. Thus, HHL caused by transient Schwann cell ablation is mechanistically distinct from that resulting from cochlear synaptopathy.

Figure 9: Synaptopathic noise exposure causes further hidden hearing loss in mice that had transient Schwann cell ablation.
Figure 9

(a) Flow chart showing the experimental design. (bd) Tamoxifen treatment induces hidden hearing loss characterized by normal ABR thresholds (b), lower ABR P1 amplitudes (c) and longer P1 latencies (d) in DTA(+/−):Plp1/Cre(+/−) mice. (eg) Hidden hearing loss caused by transient Schwann cell loss persists after noise exposure (8–16 kHz, 98 dB SPL for 2 h). Noise exposure induces further hidden hearing loss in mice with established pathology after Schwann cells loss (hj) and the control mice (km). (np) The magnitude of the noise-induced change in DTA(+/−):Plp1/Cre(+/−) mice is the same as that on DTA(+/−) mice. For np, physiological data after noise exposure were normalized to that before noise exposure within each genotype. ABR P1 amplitudes and latencies were analysed at 70 dB SPL. n=8–10 of each group. *P<0.05, **P<0.01 and ***P<0.001 by two-way ANOVA. Data are expressed as mean±s.e.m.


Myelination of the peripheral nervous system (PNS) is important for normal conduction of APs and synchronized transmission of neural impulses35,36, and damage to peripheral axons and their myelin sheaths causes many forms of peripheral neuropathy, such as CMT disease and Guillain–Barré syndrome (GBS)37,38,39. In this study, we uncover a new consequence of myelin pathology; that is, that transient Schwann cell loss results in permanent disruption of the cochlear heminodal structure and organization. We also discover that such disruption causes auditory neuropathy and HHL.

Both cochlear type I afferents (SGNs) and medial olivocochlear efferents are myelinated32; however, it is unlikely that the auditory deficits we found after transient Schwann cell ablation are caused by damage to cochlear efferent nerves. First, sound-evoked medial olivocochlear activity is greatly depressed by anaesthesia during physiological recordings, thus should contribute little to our measurements of ABR amplitudes. Most importantly, complete lesion of cochlear efferent nerves fails to impair ABR peak 1 latencies (Maison et al.40 and Liberman M.C., personal communications), further arguing against possible contribution of efferent nerves towards the auditory deficits observed in this study.

The bipolar SGNs form point-to-point connections between the sensory hair cells and neurons in the cochlear nucleus. At the SGN peripheral processes, the unmyelinated afferent terminals are tightly coupled to the ribbon synapses, whereas the myelinated axons extend from the HP to the SGN somata (Fig. 1a). Once the central SGN process enters the central nervous system (CNS), it becomes myelinated by oligodendrocytes. We used a mouse model of demyelination that results in loss of both Schwann cells in the peripheral nervous system and oligodendrocytes in the CNS. However, our physiological techniques allow us to study cochlear function without confounding issues from CNS demyelination by specifically analysing ABR peak 1. It has been shown both experimentally and computationally that ABR peak 1 is solely contributed by the IHCs and SGNs41,42, which are myelinated by Schwann cells. In addition, the first heminode at the HP formed by Schwann cells is believed to be the initial spike generator of the SGNs28,29,43. Moreover, it has been shown that in this mouse model CNS neurons remyelinate robustly and recover function after DTA-mediated oligodendrocyte ablation19, further excluding the involvement of central auditory components in this study. Thus, the physiological changes we observed after Schwann cell ablation are most likely due to alterations in the peripheral auditory components, that is, SGN synaptic terminal, axon or somata myelination or neuronal survival (refer to Fig. 1a).

Synaptic dysfunction is known to result in defects in SGN neural amplitudes and latencies6,44. However, synaptic density was not affected by Schwann cell ablation and demyelination. Although we did not examine whether synapses were transiently disrupted, it is unlikely to be that transient synaptopathy, if it occurred, could contribute to the persistent pathophysiology, as we have shown that when synapses regenerate after acute loss the auditory deficits recover as well15. As with the nerve terminals, the SGN cell bodies were also unaffected after transient loss of Schwann and satellite cells. Satellite cells express glutamine synthetase for converting ammonia and glutamate to glutamine45, which is important for metabolizing excess glutamate and preventing excitotoxicity46. Satellite cells are also important for neuronal survival as knockout of sapB from these cells resulted in progressive neuronal death47. Complete regeneration of the spiral ganglion satellite cells in our study is consistent with the remarkable spontaneous proliferation and regeneration of satellite cells in other sensory ganglia48,49,50. Timely regeneration of the satellite cells and wrapping on SGN cell bodies may be important to preserve the survival and function of the SGNs.

In animal models of central and peripheral demyelinating diseases, many axons remyelinate but with significantly thinner myelin sheaths and shorter internodal lengths51,52. Intriguingly, after transient Schwann cell loss and massive axonal demyelination in response to DTA expression, we observed complete remyelination of ANFs at the OSL featuring normal myelin thickness and nodal density. It is worth noting that DTA induction results in damage to the myelinating glial cells without directly injuring their associated neurons. In contrast, in other animal models of demyelinating disorders axons may also be injured, for example, by nerve crush or inflammation53,54. These findings suggest that intact axons, but not injured ones, are capable of providing both physical and chemical cues sufficient for normal remyelination55. Our findings are consistent with a previous report in which complete remyelination was observed in sciatic nerve after selective ablation of myelinating glial cells56. A recent report shows that in the CNS, remyelination and normal nodal length can be completely restored on small caliber axons, suggesting that complete myelin recovery may be dependent on axon caliber57. Thus, an alternative scenario is that complete remyelination of the ANFs can be attributed to their smaller axon caliber (1.5 μm diameter) compared with other peripheral nervous system axons, such as ventral roots and quadriceps nerves (>3 μm diameter)58,59.

Analysis of node of Ranvier markers indicated specific and persistent disruption of the heminodes at the HP, but with complete recovery of nodes along the axonal tracts. Emerging evidence indicates that AP generation in the auditory nerve occurs at the heminode28,29,43 and the clustering of mature heminodes may be important for tight coupling of IHC synaptic transmission and ANF spike generation29. The peak 1 of the ABR waveform, which reflects the gross ANF discharge, relies on concerted nerve conduction from the unmyelinated nerve terminals (inner spiral plexus), the heminodes (the spike generator) and the nodes of Ranvier29. The inner spiral plexus is unlikely to be involved in the observed pathophysiology, because the precisely timed short-latency nerve conduction is ensured by multiple mechanisms43. The complete recovery of nodes of Ranvier also precludes their contributions. As the highly clustered heminodes allow generation of synchronized AP spikes in multiple unisynaptic ANFs28,29,43, we propose that AP dyssynchronization resulting from heminodal disruption is the main contributor to the loss of temporal resolution in the waveform and therefore to the deterioration of peak 1 amplitude, latency and width.

The postsynaptic heminodes are typically clustered about 20 μm away from the IHC synaptic zone and are enriched in ion channels28,29. Recent studies indicate that these structural and molecular features of auditory nerve nodes and heminodes mature after the onset of hearing in rats29. Specifically, during the early postnatal ages (<P17), the immature heminodes lack Kv1.1 channels and are irregularly positioned along individual axons with about 60 μm spread from the HP29. Interestingly, the pathological heminodes observed in this study closely resembled those seen before hearing onset29. Therefore, it appears that during the process of Schwann cell regeneration, remyelination of ANFs follows a path similar to the one taking place during early postnatal development, but remyelination and heminode maturation at the HP fail to proceed, possibly due to either the presence of inhibitory signals in the mature cochlea or lack of promoting factors that are present during development. As heminodes and nodes share similar molecular microdomain structure28,29 and nodes of Ranvier recovere completely, the observed nodal pathology is likely to be due to the physical–chemical micro-environments at the HP, rather than a generic axoglial signal guiding the nodal assembly.

HHL has emerged as a major health concern13. HHL is defined and diagnosed by abnormal ABR amplitudes and latencies but normal thresholds9,10,11, thus undetectable by standard audiometry. Subjects with this type of hearing loss may have difficulties in speech discrimination and temporal processing, particularly in a noisy environment13. Until now, synaptic loss or cochlear synaptopathy resulting from either noise exposure or ageing was the only known cause of HHL5,6 and exploration of therapeutic approaches for HHL has been focused on repairing synapses15,33. Our findings indicate that HHL can also arise from pathologies of cochlear Schwann cell (schwannopathy) or nodal structures (nodopathy), rather than synaptopathy. Indeed, some patients with demyelinating disorders such as CMT disease and GBS have auditory deficits, associated with reduced ABR amplitudes and increased latencies60,61,62,63,64. Our animal model shares mechanistic similarities with GBS, where Schwann cells are specifically and transiently damaged52. Our findings that Schwann cell ablation does not affect ABR or DPOAE thresholds are consistent with rare reports of hearing threshold elevations in GBS patients63,64. Intriguingly, in those patients who suffered acute hearing loss, although hearing threshold gradually recovered, their ABR waveforms showed persistent increase in latency62. Therefore, an even greater proportion of GBS patients may have HHL that has not been diagnosed clinically. Given the growing prevalence of Zika infections, which has been shown to correlate with an increase in GBS patients worldwide65,66, the prevalence of HHL related to acute peripheral demyelinating disorders is likely to increase. Thus, the cochlear neuropathy revealed in our animal model may have clinical implications in diagnosis and eventual treatment of the different types of HHL.



Plp1/CreERT (Plp1/Cre; stock number 005975), Ai14:Rosa26tdTomato (tdTomato; stock number 007908) and Rosa26DTA (DTA; stock number 006331) transgenic mice of both genders were obtained from The Jackson Laboratory. Plp1/eGFP mice were obtained from Wendy Macklin at the University of Colorado, Denver. To express DTA in cochlear myelinating glial cells, we crossed Plp1/Cre(+/−) with DTA(+/+) mice. Cre-negative littermates were used as controls. For lineage-tracing experiments, Plp1/Cre(+/−):tdTomato(+/−) or Plp1/Cre(+/−):Plp1/eGFP(+/−) mice were crossed with DTA(+/−) mice. Offsprings carrying all three alleles were used for experiments and DTA-negative littermates were used as controls. All mice used in this work were on a mixed background containing C57Bl6 and FVB/N strains, and mice tested for auditory physiology were heterozygous for ahl allele. Both males and females were used in this study. The genotypes of the control and experimental animals were blinded to the investigators until the completion of data acquisition and analysis. All animal procedures were approved by the Institutional Animal Care and Use Committee of University of Michigan.

Tamoxifen and EdU injections

Tamoxifen (Sigma, T5648) was dissolved in corn oil (Sigma, C8267) at 37 °C to obtain 10 mg ml−1 working solution. Mice were injected i.p. with tamoxifen at 50 mg kg−1 per day from P21 to P23. Animals were analysed at 1 week to 1 year after the last tamoxifen injection. To examine cell proliferation, P29 mice were i.p. injected with EdU (obtained from the Click-iT EdU Alexa Fluor 488 Imaging Kit (Thermo Fisher Scientific, C10337)) once at 10 mg kg−1 dosage. Mice were killed and tissue analysed at P30. EdU staining was performed following the manufacturer’s instructions.

ABR and DPOAE analyses

ABRs and DPOAEs were performed on mice anaesthetized with xylazine (20 mg kg−1, i.p.) and ketamine (100 mg kg−1, i.p.). For ABR recordings, needle electrodes were placed into the skin (a) at the dorsal midline close to the neural crest, (b) behind the left pinna and (c) at the base of the tail (for a ground electrode). ABR potentials were evoked with 5 ms tone pips (0.5 ms rise–fall, with a cos2 envelope, at 40 s−1) delivered to the eardrum at log-spaced frequencies from 5.6 to 32 kHz. The response was amplified (10,000 × ) and filtered (0.3–3 kHz) with an analog-to-digital board in a PC-based data-acquisition system. Sound level was raised in 5 dB steps from 10 to 80 dB SPL. At each level, 1,024 responses were averaged (with stimulus polarity alternated) after ‘artefact rejection.’ The DPOAEs in response to two primary tones of frequency f1 and f2 were recorded at (2 × f1)−f2, with f2/f1=1.2, and the f2 level 10 dB lower than the f1 level. Ear-canal sound pressure was amplified and digitally sampled at 4 μs intervals. DPOAE thresholds were defined as the f1 level required to produce a response at −10 dB SPL. Both ABR and DPOAE recordings were performed using EPL cochlear function test suite (Mass Eye and Ear, Boston, MA, USA). ABR peak amplitudes, latencies and widths were analysed with excel and ABR peak analysis software (Mass Eye and Ear).

Noise exposure

Awake wild-type FVB/N mice or DTA(+/−):Plp1/Cre(+/−) and their control mice were placed within small cells in a subdivided cage, suspended in a reverberant noise exposure chamber. FVB/N mice (16 weeks) were exposed to an octave band of noise (8–16 kHz) at 100 dB SPL for 2 h. DTA(+/−):Plp1/Cre(+/−) and control mice (8 weeks) were exposed to the same noise at 98 dB SPL for 2 h. Calibration of noise was performed immediately before each noise overexposure to ensure that SPL levels varied by <1 dB across the cages.

Immunohistochemistry and confocal microscopy

Inner ear tissues were dissected and fixed in 4% paraformaldehyde in 0.1 M phosphate buffer for 30 min–2 h at room temperature, followed by decalcification in 5% EDTA at 4 °C for 5 days. Cochlear tissues were microdissected and permeabilized by freeze–thawing in 30% sucrose. The microdissected tissues were incubated in blocking buffer containing 5% normal horse serum and 0.3% Triton X-100 in PBS for 1 h. Tissues were then incubated in primary antibodies (diluted in blocking buffer) at 37 °C for 16 h. The primary antibodies used in this study were as follows: anti-myosin VIIa15 (rabbit anti-Myo7a; Proteus Biosciences, Ramona, CA; 1:500), anti-Sox2 (goat anti-Sox2; sc-17320, Santa Cruz Biotechnologies, Santa Cruz, CA; 1:200)16, anti-Sox10 (goat anti-Sox10; sc-17342, Santa Cruz Biotechnologies; 1:200)67, anti-MBP (rat anti-MBP; MAB386, EMD Millipore, Billerica, MA; 1:1,000)67, anti-carboxy-terminal binding protein 2 (mouse anti-Ctbp2 IgG1; BD Biosciences, San Jose, CA; 1:200)15, anti-glutamate receptor 2 (mouse anti-GluA2 IgG2a; Millipore, Billerica, MA; 1:2,000)15, anti-NFH (chicken anti-NFH; AB5539, EMD Millipore; 1:2,000)31, anti-Plp1 (gift of Wendy Macklin; 1:500)16, anti-Caspr (gift of Roman Giger; 1:1,000)68, anti-gliomedin (gift of Elior Peles; 1:500)30, anti-pan sodium channel (anti-NaV; gift of Roman Giger; 1:75)68, anti-β4-spectrin and anti-Ankyrin G (gifts of Paul Jenkins; 1:500)69. Tissues were then incubated with appropriate Alexa Fluor-conjugated fluorescent secondary antibodies (Invitrogen, Carlsbad, CA; 1:500 in blocking buffer) for 1 h at room temperature. Nuclei were labelled with either 4,6-diamidino-2-phenylindole (1 μg ml−1; Life Technologies) or Hoechst 33342 (1:2,000; Life Technologies). The tissues were mounted on microscope slides in ProLong Gold Antifade Mountant (P36930, Thermo Fisher Scientific). Unless otherwise stated, mid-apical cochlear tissues (8–16 kHz region) were used for analyses.

Confocal z-stacks (0.3 μm step size) of cochlear tissues were taken using either a Zeiss LSM710 or a Leica SP8 microscope equipped with × 40 and × 63 oil-immersion lens. Images for quantitative analyses of the nodal structures were taken under × 63 lens with × 5 optical zoom. Imaging and analyses of cochlear ribbon synapses were performed as previously described15. ImageJ software (version 1.46r, NIH, MD) was used for image processing and three-dimensional reconstruction of z-stacks. All immunofluorescence images shown are representative of at least three individual mice each group.

Plastic sections and transmission electron microscopy

Mice were perfused intracardially with 4% paraformaldehyde in 0.1 M phosphate buffer. Cochleae were then extracted and postfixed with 1.5% paraformaldehyde and 2.5% glutaraldehyde, followed by osmification in 1% osmium tetroxide, decalcification in 5% EDTA, dehydration in ethanol and embedding in araldite resin. The embedded cochleae were hardened at 60 °C for 5 days before semi-thin (1 μm) plastic sectioning for light microscopy and ultra-thin (70 nm) sectioning for transmission electron microscopy using a Leica UC6 ultramicrotome. The semi-thin sections were mounted on microscope slides in Permount (Fisher Scientific) and the SGN cell bodies imaged under light microscope using × 63 lens.

Ultra-thin sections were sequentially poststained with 6% w/v uranyl acetate and 4.4% w/v lead citrate. Transmission electron microscopy was performed on Jeol 1400-plus electron microscope (Jeol USA, Peabody, MA). Multiple non-overlapping regions of the ANF cross-sections were imaged at × 3,400 magnification. The circumference of each axon fibre and axon fibre plus myelin sheath was measured using ImageJ software. Axon diameters were estimated as circumference/π and the g-ratio was calculated as axon diameter / (axon+myelin sheath diameter). Axons with circularity (4 × π × area/perimeter2) under 6 were excluded from analysis. All images of semi-thin sections and electron microscope sections shown are representative of at least three individual mice each group.

Statistical analysis

Statistical tests were performed using Graphpad Prism 6 (Graphpad Software Inc., La Jolla, CA). Distribution of the data was assumed to be normal, but this was not formally tested. No statistical methods were used predetermine sample sizes, but our sample sizes are similar to those reported in our previous publications15,16,70. Statistical differences in auditory physiology, ribbon synapse counts, densities of myelinated axons, densities of nodes and aberrant nodes were analysed using two-way ANOVA, followed by Bonferroni’s multiple comparisons test. Densities of SGN cell bodies and percentages of SGN cell bodies wrapped by satellite cells were compared using unpaired Student’s t-test. χ2-test and frequency distribution plots were used to compare the distribution of axon diameters and g-ratios (axon diameter/(axon+myelin sheath diameter) (300–500 axons from 3 mice per group). Student’s t-test was also used to compare the average axon diameter and g-ratio of each mouse.

Data availability

All relevant data are included in the manuscript or its Supplementary Information and available from the authors upon request.

Additional information

How to cite this article: Wan, G. & Corfas, G. Transient auditory nerve demyelination as a new mechanism for hidden hearing loss. Nat. Commun. 8, 14487 doi: 10.1038/ncomms14487 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    , & The global burden of disabling hearing impairment: a call to action. Bull. World Health Org. 92, 367–373 (2014).

  2. 2.

    , , & Clinical measures of auditory function: the cochlea and beyond. Dis. Mon. 59, 147–156 (2013).

  3. 3.

    & Tinnitus with a normal audiogram: physiological evidence for hidden hearing loss and computational model. J. Neurosci. 31, 13452–13457 (2011).

  4. 4.

    , & Dynamics of cochlear synaptopathy after acoustic overexposure. J. Assoc. Res. Otolaryngol. 16, 205–219 (2015).

  5. 5.

    , , & Age-related cochlear synaptopathy: an early-onset contributor to auditory functional decline. J. Neurosci. 33, 13686–13694 (2013).

  6. 6.

    & Adding insult to injury: cochlear nerve degeneration after ‘temporary’ noise-induced hearing loss. J. Neurosci. 29, 14077–14085 (2009).

  7. 7.

    , , , & Cochlear neuropathy and the coding of supra-threshold sound. Front. Syst. Neurosci. 8, 26 (2014).

  8. 8.

    et al. Auditory brainstem response latency in noise as a marker of cochlear synaptopathy. J. Neurosci. 36, 3755–3764 (2016).

  9. 9.

    , , , & Toward a differential diagnosis of hidden hearing loss in humans. PLoS ONE 11, e0162726 (2016).

  10. 10.

    & No longer falling on deaf ears: mechanisms of degeneration and regeneration of cochlear ribbon synapses. Hear. Res. 329, 1–10 (2015).

  11. 11.

    & Synaptopathy in the noise-exposed and aging cochlea: primary neural degeneration in acquired sensorineural hearing loss. Hear. Res. 330, 191–199 (2015).

  12. 12.

    et al. Non-monotonic relation between noise exposure severity and neuronal hyperactivity in the auditory midbrain. Front. Neurol. 7, 133 (2016).

  13. 13.

    Hidden hearing loss. Sci. Am. 313, 48–53 (2015).

  14. 14.

    The ultrastructure of the organ of Corti. Int. Rev. Cytol. 42, 173–222 (1975).

  15. 15.

    , , , & Neurotrophin-3 regulates ribbon synapse density in the cochlea and induces synapse regeneration after acoustic trauma. eLife 3, e03564 (2014).

  16. 16.

    et al. Spontaneous regeneration of cochlear supporting cells after neonatal ablation ensures hearing in the adult mouse. Proc. Natl Acad. Sci. USA 111, 16919–16924 (2014).

  17. 17.

    , & Inner ear supporting cells: rethinking the silent majority. Semin. Cell Dev. Biol. 24, 448–459 (2013).

  18. 18.

    , , & Cell-specific inducible gene recombination in postnatal inner ear supporting cells and glia. J. Assoc. Res. Otolaryngol. 11, 19–26 (2010).

  19. 19.

    et al. A genetic mouse model of adult-onset, pervasive central nervous system demyelination with robust remyelination. Brain 133, 3017–3029 (2010).

  20. 20.

    Remyelination in the central nervous system and the peripheral nervous system. Adv. Neurol. 47, 215–254 (1988).

  21. 21.

    & Proliferation of Schwann cells in demyelinated rat sciatic nerve. Acta Neuropathol. 71, 251–258 (1986).

  22. 22.

    & Negative regulation of myelination: relevance for development, injury, and demyelinating disease. Glia 56, 1552–1565 (2008).

  23. 23.

    & Signals regulating myelination in peripheral nerves and the Schwann cell response to injury. Curr. Opin. Neurobiol. 23, 1041–1048 (2013).

  24. 24.

    & Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve 12, 435–451 (1989).

  25. 25.

    et al. Long-term analyses of innervation and neuromuscular integrity in the Trembler-J mouse model of Charcot-Marie-Tooth disease. J. Neuropathol. Exp. Neurol. 72, 942–954 (2013).

  26. 26.

    et al. Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis. Nat. Rev. Neurol. 11, 711–724 (2015).

  27. 27.

    et al. The axonal membrane protein Caspr, a homologue of neurexin IV, is a component of the septate-like paranodal junctions that assemble during myelination. J. Cell Biol. 139, 1495–1506 (1997).

  28. 28.

    , , , & Where is the spike generator of the cochlear nerve? Voltage-gated sodium channels in the mouse cochlea. J. Neurosci. 25, 6857–6868 (2005).

  29. 29.

    & Maturation of NaV and KV channel topographies in the auditory nerve spike initiator before and after developmental onset of hearing function. J. Neurosci. 36, 2111–2118 (2016).

  30. 30.

    et al. Gliomedin mediates Schwann cell-axon interaction and the molecular assembly of the nodes of Ranvier. Neuron 47, 215–229 (2005).

  31. 31.

    , , & Primary neural degeneration in the Guinea pig cochlea after reversible noise-induced threshold shift. J. Assoc. Res. Otolaryngol. 12, 605–616 (2011).

  32. 32.

    Further morphological modifications of the concept of efferent cochlear innervation at an ultrastructural level. J. Laryngol. Otol. 87, 619–638 (1973).

  33. 33.

    , & Round-window delivery of neurotrophin 3 regenerates cochlear synapses after acoustic overexposure. Sci. Rep. 6, 24907 (2016).

  34. 34.

    et al. Noise-induced damage to ribbon synapses without permanent threshold shifts in neonatal mice. Neuroscience 304, 368–377 (2015).

  35. 35.

    Regulation of conduction time along axons. Neuroscience 276, 126–134 (2014).

  36. 36.

    Schwann cell myelination. Cold Spring Harb. Perspect. Biol. 7, a020529 (2015).

  37. 37.

    , & Schwann cells and the pathogenesis of inherited motor and sensory neuropathies (Charcot-Marie-Tooth disease). Glia 54, 243–257 (2006).

  38. 38.

    & Schwann cell-axon interactions in Charcot-Marie-Tooth disease. Ann. N. Y. Acad. Sci. 883, 77–90 (1999).

  39. 39.

    Pathophysiology of autoimmune polyneuropathies. Press. Med. 42, e181–e192 (2013).

  40. 40.

    , & Efferent feedback minimizes cochlear neuropathy from moderate noise exposure. J. Neurosci. 33, 5542–5552 (2013).

  41. 41.

    Auditory evoked potentials recorded directly from the human VIIIth nerve and brain stem: origins of their fast and slow components. Electroencephal. Clin. Neurophysiol. Suppl. 36, 305–314 (1982).

  42. 42.

    & Peak I of the human auditory brainstem response results from the somatic regions of type I spiral ganglion cells: evidence from computer modeling. Hear. Res. 315, 67–79 (2014).

  43. 43.

    , & Spike encoding of neurotransmitter release timing by spiral ganglion neurons of the cochlea. J. Neurosci. 32, 4773–4789 (2012).

  44. 44.

    et al. Onset coding is degraded in auditory nerve fibers from mutant mice lacking synaptic ribbons. J. Neurosci. 30, 7587–7597 (2010).

  45. 45.

    , & Glutamine synthetase and glutamate metabolism in the guinea pig cochlea. Hear. Res. 101, 93–101 (1996).

  46. 46.

    , & Glutamine synthetase in brain: effect of ammonia. Neurochem. Int. 41, 123–142 (2002).

  47. 47.

    et al. Spiral ganglion degeneration and hearing loss as a consequence of satellite cell death in saposin B-deficient mice. J. Neurosci. 35, 3263–3275 (2015).

  48. 48.

    , & Satellite cell proliferation in murine sensory ganglia in response to scarification of the skin. Glia 45, 105–109 (2004).

  49. 49.

    , & Satellite glial cells surrounding primary afferent neurons are activated and proliferate during monoarthritis in rats: is there a role for ATF3? PLoS ONE 9, e108152 (2014).

  50. 50.

    , , , & Satellite glial cell proliferation in the trigeminal ganglia after chronic constriction injury of the infraorbital nerve. Glia 61, 2000–2008 (2013).

  51. 51.

    , , & Pushing forward: remyelination as the new frontier in CNS diseases. Trends Neurosci. 39, 246–263 (2016).

  52. 52.

    & Axonal Guillain-Barre syndrome: concepts and controversies. Lancet Neurol. 12, 1180–1188 (2013).

  53. 53.

    & Mechanisms of distal axonal degeneration in peripheral neuropathies. Neurosci. Lett. 596, 33–50 (2015).

  54. 54.

    & Nerve injury, axonal degeneration and neural regeneration: basic insights. Brain Pathol. 9, 313–325 (1999).

  55. 55.

    et al. Axonally derived neuregulin-1 is required for remyelination and regeneration after nerve injury in adulthood. J. Neurosci. 31, 3225–3233 (2011).

  56. 56.

    et al. Targeted ablation of oligodendrocytes induces axonal pathology independent of overt demyelination. J. Neurosci. 32, 8317–8330 (2012).

  57. 57.

    et al. Remyelination reporter reveals prolonged refinement of spontaneously regenerated myelin. Proc. Natl Acad. Sci. USA 110, 4075–4080 (2013).

  58. 58.

    , , & Distal axonopathy in peripheral nerves of PMP22-mutant mice. Brain 122, 1563–1577 (1999).

  59. 59.

    et al. Requirement of heavy neurofilament subunit in the development of axons with large calibers. J. Cell Biol. 143, 195–205 (1998).

  60. 60.

    et al. A unique point mutation in the PMP22 gene is associated with Charcot-Marie-Tooth disease and deafness. Am. J. Hum. Genet. 64, 1580–1593 (1999).

  61. 61.

    et al. Late-onset Charcot-Marie-Tooth type 2 disease with hearing impairment associated with a novel Pro105Thr mutation in the MPZ gene. Am. J. Med. Genet. 143A, 2196–2199 (2007).

  62. 62.

    et al. Sudden deafness and facial diplegia in Guillain-Barre Syndrome: radiological depiction of facial and acoustic nerve lesions. Int. Med. 51, 2433–2437 (2012).

  63. 63.

    , & Acoustic nerve conduction abnormalities in Guillain-Barre syndrome. Neurology 38, 1263–1266 (1988).

  64. 64.

    , & Brainstem auditory evoked potentials in Guillain-Barre syndrome. Neurology 35, 771–773 (1985).

  65. 65.

    et al. Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 387, 1531–1539 (2016).

  66. 66.

    , & Zika virus-associated neurological disease in the adult: guillain-Barre syndrome, encephalitis, and myelitis. Semin. Reprod. Med. 34, 273–279 (2016).

  67. 67.

    et al. Distribution and development of peripheral glial cells in the human fetal cochlea. PLoS ONE 9, e88066 (2014).

  68. 68.

    et al. Congenital CNS hypomyelination in the Fig4 null mouse is rescued by neuronal expression of the PI(3,5)P(2) phosphatase Fig4. J. Neurosci. 31, 17736–17751 (2011).

  69. 69.

    , , , & Giant ankyrin-G stabilizes somatodendritic GABAergic synapses through opposing endocytosis of GABAA receptors. Proc. Natl Acad. Sci. USA 112, 1214–1219 (2015).

  70. 70.

    et al. Nonneuronal cells regulate synapse formation in the vestibular sensory epithelium via erbB-dependent BDNF expression. Proc. Natl Acad. Sci. USA 107, 17005–17010 (2010).

Download references


We thank Roman Giger (University of Michigan) for Caspr and NaV antibodies, Paul Jenkins (University of Michigan) for AnkG and β4-spectrin antibodies, Elior Peles (Weizmann Institute of Science) for gliomedin antibodies, Angelica Gigliello for technical assistance and staff at the University of Michigan Microscopy & Image Analysis Laboratory core for help in electron microscopy. We thank M. Charles Liberman, Jochen Schacht, Susan Shore, James Teener and Roman Giger for critical reading of the manuscript. This study is supported by NIH/NIDCD R01DC004820 (to G.C.) and Hearing Health Foundation (to G.W.).

Author information


  1. Department of Otolaryngology–Head and Neck Surgery, Kresge Hearing Research Institute, University of Michigan, 1150 West Medical Center Drive, Ann Arbor, Michigan 48109, USA

    • Guoqiang Wan
    •  & Gabriel Corfas
  2. MOE Key Laboratory of Model Animals for Disease Study, Model Animal Research Center of Nanjing University, Nanjing, Jiangsu Province, China

    • Guoqiang Wan


  1. Search for Guoqiang Wan in:

  2. Search for Gabriel Corfas in:


G.W. and G.C. designed the study. G.W. performed the experiments and analysed the data. G.W. and G.C. interpreted the data and wrote the manuscript.

Competing interests

G.C. is a scientific founder of Decibel Therapeutics, has an equity interest in and has received compensation for consulting. The company was not involved in this study. G.W. declares no competing financial interest

Corresponding authors

Correspondence to Guoqiang Wan or Gabriel Corfas.

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    Supplementary Figures.

  2. 2.

    Peer Review File


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Creative Commons BYThis work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit